Non-Ergot Dopamine Agonists And Heart Failure

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials.

BACKGROUND In recent years, some observational studies suggested that pramipexole, a non-ergot dopamine agonist (DA) used for the treatment of Parkinson's disease (PD), may increase the risk of heart failure (HF). However, the limitations inherent in observational studies made it difficult to determine whether the excess of incident HF was related to the drug or to other determinants. Thus, som...

متن کامل

Is there any difference between Vitamin D deficiency among heart failure and Non-heart failure elderly with cardiovascular disease?

Vitamin D deficiency is common among the elderly with and without heart failure (HF). This study was designed to identify the degree of vitamin D deficiency among HF and Non- HF elderly with cardiovascular disease. In this study, fifty hospitalized elderly patients with HF (26 women and 24 men, age range 60-90 years) and fifty elderly without HF were randomly selected. The level of serum 25-hyd...

متن کامل

Dopamine Agonists

Dopamine agonists (DA) have been used to treat symptoms of Parkinson’s disease (PD) since the late 1970s (1). These agents were initially introduced to supplement the beneficial effect and possibly reduce the incidence of longterm complications of levodopa. In the last 30 years, methodical investigations of DA have demonstrated therapeutic benefit in all stages of PD both in combination with le...

متن کامل

Risk of non-fatal cardiac failure and ischaemic heart disease with long acting â2 agonists

Background—The long term safety of â agonists, particularly in patients with heart disease, has not been fully established. Methods—This study accessed the results of three cohort studies involving: 12 294 patients receiving at least one prescription for nedocromil between November 1986 and September 1988; 15 407 patients prescribed salmeterol between December 1990 and May 1991; and 8098 patien...

متن کامل

Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.

BACKGROUND The long term safety of beta agonists, particularly in patients with heart disease, has not been fully established. METHODS This study accessed the results of three cohort studies involving: 12,294 patients receiving at least one prescription for nedocromil between November 1986 and September 1988; 15,407 patients prescribed salmeterol between December 1990 and May 1991; and 8098 p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: The Anatolian Journal of Cardiology

سال: 2018

ISSN: 2149-2263

DOI: 10.14744/anatoljcardiol.2018.76299